Synthesis, Characterisation, and In Vitro Anticancer Activity of Curcumin Analogues Bearing Pyrazole/Pyrimidine Ring Targeting EGFR Tyrosine Kinase

Table 2

Sixty human tumor cell lines anticancer screening data of curcumin analogues (1–14).

Panel/cell line	Growth percent in one-dose assay
	1	2	3	5	6	8	10	11	12	13
Leukemia
CCRF-CEM	−4.54	4.45	6.82	0.87	0.44	1.54	−5.12	3.52	16.72	1.68
HL-60(TB)	−24.28	−20.94	−21.36	−28.92	−28.17	−30.36	−42.20	−23.89	61.33	3.67
K-562	2.27	−7.30	0.22	−3.90	2.29	−7.18	−15.52	3.62	42.03	5.49
MOLT-4	−4.57	−2.00	−3.56	−17.67	0.11	−20.68	−39.87	−6.53	36.34	4.17
RPMI-8226	−22.31	2.91	3.32	−11.32	−14.46	−16.73	−33.60	14.25	62.49	2.88
SR	−17.72	1.52	2.53	1.44	−14.65	−2.07	−13.89	−4.77	27.24	−7.94
Non-small-cell lung cancer
A549/ATCC	8.75	4.03	12.02	5.90	4.71	−3.98	8.40	41.73	71.68	10.09
EKVX	17.68	16.85	26.87	−17.67	20.29	−14.72	−38.79	30.55	71.60	22.16
HOP-62	8.39	17.06	30.22	−7.78	11.62	−35.66	−67.73	43.53	70.77	4.85
HOP-92	−14.42	−4.70	−3.45	NT	−15.38	−27.02	NT	NT	33.70	−21.24
NCI-H226	−3.72	5.73	15.88	−4.32	−0.89	−3.70	−8.19	38.48	76.20	11.70
NCI-H23	−25.82	3.16	10.74	−12.87	−10.41	−26.09	NT	17.66	62.85	−2.79
NCI-H322M	NT	22.13	27.32	12.63	NT	8.13	−3.64	39.48	NT	NT
NCI-H460	7.39	9.41	8.35	4.43	10.14	1.87	−0.07	9.15	69.70	5.54
NCI-H522	−18.66	−4.94	−6.04	10.89	−19.34	6.31	−30.23	4.20	54.59	−41.31
Colon cancer
COLO 205	−73.49	7.57	8.73	59.43	−25.81	−65.55	−84.05	23.87	51.81	−50.38
HCC-2998	2.83	4.55	6.92	9.75	2.19	4.28	5.82	40.94	70.99	0.93
HCT-116	1.16	4.61	4.95	2.15	1.60	1.48	−5.83	6.90	34.75	0.33
HCT-15	15.05	7.86	10.63	6.64	15.22	3.84	−3.38	16.21	81.79	29.55
HT29	−34.95	−11.07	−41.84	−33.57	−22.35	−38.54	−52.39	0.38	−6.41	−76.24
KM12	0.09	3.53	2.44	0.08	−1.13	−9.35	−27.96	4.98	29.26	−29.25
SW-620	6.99	9.56	10.52	2.03	8.12	−10.94	−22.72	20.86	43.58	1.86
CNS cancer
SF-268	−6.38	13.87	20.12	6.57	−11.50	3.80	−12.52	27.97	48.19	3.56
SF-295	2.83	−21.89	−21.61	−55.32	0.53	−51.02	−71.47	−29.68	92.76	−5.25
SF-539	4.06	0.16	3.68	−16.58	5.95	−19.58	−39.79	4.02	69.02	11.95
SNB-19	15.49	9.25	20.15	4.42	20.27	2.45	1.18	36.22	82.60	23.19
SNB-75	−4.71	18.75	26.93	−12.60	9.53	−30.53	−53.18	27.28	44.32	5.50
U251	2.33	4.31	13.38	−1.59	6.19	−12.27	−1.47	35.06	55.64	2.97
Melanoma
LOX IMVI	1.22	3.04	4.00	−20.87	1.89	−29.79	−37.11	9.29	49.04	−16.09
MALME-3M	8.27	3.94	9.15	−16.80	17.27	−21.70	−38.98	23.43	53.57	−28.85
M14	0.26	4.04	2.69	−21.86	2.30	−38.14	−55.95	5.42	75.46	−26.13
MDA-MB-435	4.08	2.46	−2.32	−25.94	−1.64	−40.91	−67.34	−30.53	56.89	−8.12
SK-MEL-2	−12.27	−23.52	−27.07	−25.00	−13.98	−27.22	−48.11	−0.33	81.15	−21.01
SK-MEL-28	12.10	12.72	16.70	7.87	13.22	5.57	−6.73	28.64	50.89	9.55
SK-MEL-5	−23.76	−29.66	−8.36	−73.86	1.16	−83.44	−86.52	−1.91	70.74	−18.40
UACC-257	1.28	3.11	13.66	−15.89	4.80	−21.42	16.03	87.13	62.46	−1.90
UACC-62	1.04	4.06	2.01	−37.42	0.49	−48.47	−84.39	3.48	63.31	−57.66
Ovarian cancer
IGROV1	−6.58	9.93	17.41	4.57	4.76	−1.75	−21.18	24.95	93.12	3.42
OVCAR-3	−26.77	−10.97	3.89	−26.44	−34.15	−37.33	−46.92	12.55	59.34	−7.57
OVCAR-4	6.59	13.25	35.55	9.26	16.08	7.87	4.49	49.80	53.98	18.31
OVCAR-5	13.18	10.94	31.32	0.88	20.53	−4.24	−7.74	84.49	101.67	5.83
OVCAR-8	1.50	−19.83	0.47	−44.00	−2.98	−34.66	−13.11	27.73	58.71	9.33
NCI/ADR-RES	20.83	17.46	27.91	12.01	20.50	7.64	3.18	28.13	90.66	39.32
SK-OV-3	−33.32	−0.37	−18.66	−31.16	−29.09	−63.58	−53.08	16.55	71.63	−17.39
Renal cancer
786-0	−14.80	−2.20	−6.90	−32.92	−1.18	−59.07	−76.67	9.91	82.57	−58.93
A498	−11.83	−0.60	31.49	−13.65	12.02	−14.70	−25.17	56.41	62.76	−56.92
ACHN	2.83	9.29	20.22	5.73	16.12	5.25	2.77	25.12	89.36	13.46
CAKI-1	7.29	0.13	−7.81	−39.10	8.65	−36.63	−60.45	−34.77	88.61	19.24
RXF 393	−50.32	−53.60	−43.84	−57.61	−47.46	−67.29	−70.03	−3.83	23.75	−63.92
SN 12C	14.20	9.00	17.95	2.06	18.30	0.47	−3.11	14.23	62.26	22.14
TK-10	16.15	23.10	38.12	24.04	28.55	15.86	6.18	65.02	102.74	21.38
UO-31	−34.84	2.71	14.05	−16.95	0.97	−38.74	−44.64	23.86	54.25	3.16
Prostate cancer
PC-3	6.54	4.24	9.01	−14.26	8.08	−10.82	−33.14	12.92	61.01	12.99
DU-145	1.23	11.66	6.77	−11.84	2.20	−26.64	−45.74	28.87	80.37	13.04
Breast cancer
MCF7	4.41	5.36	9.49	2.06	6.30	−3.78	−5.71	20.22	52.10	7.59
MDA-MB-231/ATCC	17.71	14.35	33.61	12.24	19.94	10.25	5.23	39.69	54.19	3.39
HS 578T	−4.71	8.23	20.04	−12.92	−15.97	−14.33	−12.98	3.59	53.91	−1.00
BT-549	−26.40	−14.35	−8.33	−24.17	−23.00	−33.81	−47.16	14.49	55.03	−24.41
T-47D	4.55	18.50	31.15	2.29	5.65	−22.55	−23.93	48.99	59.14	1.57
MDA-MB-468	−24.19	−26.40	−14.60	−27.56	−29.14	−30.34	−31.86	2.97	6.34	−35.04
Mean	−4.66	1.81	7.23	−12.25	−0.66	−19.19	−28.71	19.03	59.94	−5.46
Range	94.32	76.70	81.96	97.90	76.01	99.30	102.55	121.90	109.15	115.56

NT: not tested.